Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zoledronic acid oral - Merrion

Next Previous
X
Search
Drug Profile

Zoledronic acid oral - Merrion

Alternative Names: MER-101; Orazol

Latest Information Update: 20 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merrion Pharmaceuticals
  • Class Antineoplastics; Bisphosphonates; Calcium regulators; Imidazoles; Osteoporosis therapies; Small molecules
  • Mechanism of Action Geranyltranstransferase inhibitors; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Bone metastases

Most Recent Events

  • 10 Sep 2015 No recent reports on development identified - Phase-II for Bone metastases in USA, Estonia and Latvia (PO)
  • 16 Nov 2010 Zoledronic acid oral is still in phase II trials in USA
  • 20 Oct 2009 Pharmacokinetics data from a clinical trial released by Merrion Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top